Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Leases (2019 - 2025)

Voyager Therapeutics (VYGR) has disclosed Current Leases for 7 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 8.48% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 8.48% year-over-year, with the annual reading at $7.8 million for FY2025, 8.48% up from the prior year.
  • Current Leases hit $7.8 million in Q4 2025 for Voyager Therapeutics, roughly flat from $7.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.8 million in Q3 2025 to a low of $2.5 million in Q2 2022.
  • Historically, Current Leases has averaged $5.2 million across 5 years, with a median of $5.4 million in 2021.
  • Biggest five-year swings in Current Leases: tumbled 49.17% in 2022 and later surged 125.84% in 2024.
  • Year by year, Current Leases stood at $5.6 million in 2021, then crashed by 49.17% to $2.8 million in 2022, then increased by 12.99% to $3.2 million in 2023, then soared by 125.84% to $7.2 million in 2024, then increased by 8.48% to $7.8 million in 2025.
  • Business Quant data shows Current Leases for VYGR at $7.8 million in Q4 2025, $7.8 million in Q3 2025, and $7.6 million in Q2 2025.